• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手部湿疹严重程度指数(HECSI)的效度、信度及检测变化能力评估,以及将HECSI-75和HECSI-90作为患者内缓解定义的评估。

Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions.

作者信息

Yüksel Yasemin Topal, Thoning Henrik, Larsen Lotte Seiding, Lehmann Lucine, Arbuckle Rob, Grant Laura, Agner Tove

机构信息

Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

LEO Pharma A/S, Ballerup, Denmark.

出版信息

Contact Dermatitis. 2025 Jan;92(1):51-60. doi: 10.1111/cod.14699. Epub 2024 Oct 13.

DOI:10.1111/cod.14699
PMID:39396828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11669562/
Abstract

BACKGROUND

The Hand Eczema Severity Index (HECSI) is a Clinician-Reported Outcome measure of the severity of hand eczema (HE).

OBJECTIVES

This study aimed to evaluate the validity, reliability and ability to detect change of the HECSI, and the HECSI-75 and HECSI-90 as responder definitions.

METHODS

Analyses were performed using data from a sample of n = 258 patients with Chronic Hand Eczema (CHE) from a Phase 2b, randomised, double-blind, vehicle-controlled trial of delgocitinib cream, pooled across treatment groups. The measurement properties of the HECSI were assessed and the adequacy of the HECSI-75 and HECSI-90 as responder definitions was explored through cross-tabulation.

RESULTS

Inter-item correlations provided support for the scoring, whereby items are grouped by areas of the hand. HECSI demonstrated good test-retest reliability with intra-class correlations >0.70. Construct validity was supported by a logical pattern of correlations with concurrent measures and significant differences in HECSI scores across severity groups (p < 0.001). HECSI was responsive with statistically significant improvements over time and with significant differences (p < 0.001) between improved and stable groups. Data provided support for both HECSI-75 and HECSI-90 as within-patient responder definitions.

CONCLUSIONS

HECSI has strong validity, reliability and ability to detect change as a measure of CHE severity. HECSI-75 and HECSI-90 are appropriate responder definitions.

摘要

背景

手部湿疹严重程度指数(HECSI)是一种由临床医生报告的手部湿疹(HE)严重程度的指标。

目的

本研究旨在评估HECSI、HECSI-75和HECSI-90作为反应者定义的有效性、可靠性和检测变化的能力。

方法

使用来自2b期随机双盲赋形剂对照的地尔泊替尼乳膏试验中n = 258例慢性手部湿疹(CHE)患者样本的数据进行分析,数据汇总自各治疗组。评估HECSI的测量属性,并通过交叉表探索HECSI-75和HECSI-90作为反应者定义的充分性。

结果

项目间相关性为评分提供了支持,其中项目按手部区域分组。HECSI显示出良好的重测信度,组内相关性>0.70。结构效度得到与同时测量的逻辑相关模式以及不同严重程度组间HECSI评分的显著差异(p < 0.001)的支持。HECSI有反应性,随着时间推移有统计学显著改善,改善组和稳定组之间有显著差异(p < 0.001)。数据为HECSI-75和HECSI-90作为患者内反应者定义提供了支持。

结论

HECSI作为CHE严重程度的一种测量方法,具有很强的有效性、可靠性和检测变化的能力。HECSI-75和HECSI-90是合适的反应者定义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9da0/11669562/59900e09b60a/COD-92-51-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9da0/11669562/59900e09b60a/COD-92-51-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9da0/11669562/59900e09b60a/COD-92-51-g001.jpg

相似文献

1
Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions.手部湿疹严重程度指数(HECSI)的效度、信度及检测变化能力评估,以及将HECSI-75和HECSI-90作为患者内缓解定义的评估。
Contact Dermatitis. 2025 Jan;92(1):51-60. doi: 10.1111/cod.14699. Epub 2024 Oct 13.
2
Assessment of hand eczema severity by patients using the hand eczema severity index (HECSI).患者使用手部湿疹严重指数(HECSI)评估手部湿疹严重程度。
J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2349-2354. doi: 10.1111/jdv.19329. Epub 2023 Jul 24.
3
Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS).慢性手部湿疹对健康相关生活质量影响的患者报告结局量表的开发与验证:手部湿疹影响量表(HEIS)
Dermatol Ther (Heidelb). 2024 Nov;14(11):3047-3070. doi: 10.1007/s13555-024-01267-0. Epub 2024 Oct 21.
4
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD).用于评估慢性手部湿疹体征和症状的患者报告结局量表的开发与心理测量学验证:手部湿疹症状日记(HESD)
Dermatol Ther (Heidelb). 2024 Mar;14(3):643-669. doi: 10.1007/s13555-024-01114-2. Epub 2024 Mar 15.
5
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity.验证研究者整体评估慢性手部湿疹(IGA-CHE):一种新的评估 CHE 严重程度的临床医生报告结局指标。
Arch Dermatol Res. 2024 Mar 20;316(4):110. doi: 10.1007/s00403-024-02818-3.
6
Responsiveness and interpretability of the Hand Eczema Severity Index.手部湿疹严重程度指数的反应性与可解释性。
Br J Dermatol. 2020 Apr;182(4):932-939. doi: 10.1111/bjd.18295. Epub 2019 Sep 5.
7
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.在一项为期 16 周的随机 2b 期临床试验中,乳膏制剂的泛 JAK 抑制剂地洛格司亭在慢性手部湿疹中表现出剂量反应。
Br J Dermatol. 2022 Jul;187(1):42-51. doi: 10.1111/bjd.21037. Epub 2022 Apr 19.
8
The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability.手部湿疹严重程度指数(HECSI):一种用于手部湿疹临床评估的评分系统。观察者间及观察者内可靠性研究。
Br J Dermatol. 2005 Feb;152(2):302-7. doi: 10.1111/j.1365-2133.2004.06305.x.
9
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.多中心、随机、对照、双盲、III 期临床试验:delgocitinib 乳膏治疗成人中重度慢性手部湿疹的疗效和安全性(DELTA 1 和 DELTA 2)。
Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18.
10
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.在患有慢性手部湿疹的成人中,使用delgocitinib乳膏长达52周的长期安全性和有效性:DELTA 1和2试验之后的3期开放标签扩展DELTA 3试验结果。
J Am Acad Dermatol. 2025 Mar 11. doi: 10.1016/j.jaad.2025.03.008.

引用本文的文献

1
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema.20毫克/克地尔古替尼乳膏:慢性手部湿疹综述
Drugs. 2025 Jul 14. doi: 10.1007/s40265-025-02206-9.
2
Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice.意大利慢性手部湿疹专家意见:从指南到临床实践
Dermatol Ther (Heidelb). 2025 Jan;15(1):75-93. doi: 10.1007/s13555-024-01312-y. Epub 2024 Nov 28.

本文引用的文献

1
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity.验证研究者整体评估慢性手部湿疹(IGA-CHE):一种新的评估 CHE 严重程度的临床医生报告结局指标。
Arch Dermatol Res. 2024 Mar 20;316(4):110. doi: 10.1007/s00403-024-02818-3.
2
Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial.使用地洛昔芬乳膏治疗可改善慢性手部湿疹的瘙痒、疼痛和其他症状和体征:来自 IIb 期随机临床试验手部湿疹症状日记的结果。
Contact Dermatitis. 2023 Jul;89(1):46-53. doi: 10.1111/cod.14303. Epub 2023 Apr 10.
3
Validation of the Danish version of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
手部湿疹生活质量问卷(QOLHEQ)丹麦语版本的验证。
Br J Dermatol. 2022 Aug;187(2):256-258. doi: 10.1111/bjd.21041. Epub 2022 May 4.
4
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.在一项为期 16 周的随机 2b 期临床试验中,乳膏制剂的泛 JAK 抑制剂地洛格司亭在慢性手部湿疹中表现出剂量反应。
Br J Dermatol. 2022 Jul;187(1):42-51. doi: 10.1111/bjd.21037. Epub 2022 Apr 19.
5
Guidelines for diagnosis, prevention, and treatment of hand eczema.手部湿疹的诊断、预防及治疗指南。
Contact Dermatitis. 2022 May;86(5):357-378. doi: 10.1111/cod.14035. Epub 2022 Mar 3.
6
New evidence on the minimal important change (MIC) for the Hand Eczema Severity Index (HECSI).手部湿疹严重程度指数(HECSI)最小重要变化(MIC)的新证据。
Contact Dermatitis. 2021 Mar 3. doi: 10.1111/cod.13828.
7
Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges.治疗慢性手部湿疹的药物:成就与关键挑战
Ther Clin Risk Manag. 2020 Dec 31;16:1319-1332. doi: 10.2147/TCRM.S292504. eCollection 2020.
8
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).特利鲁单抗治疗中重度特应性皮炎的两项 52 周、随机、双盲、多中心、安慰剂对照 III 期临床试验(ECZTRA1 和 ECZTRA2)结果。
Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.
9
Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists.基于患者和皮肤科专家定性访谈的慢性手部湿疹(CHE)概念模型的构建。
Adv Ther. 2020 Feb;37(2):692-706. doi: 10.1007/s12325-019-01164-5. Epub 2020 Jan 19.
10
Responsiveness and interpretability of the Hand Eczema Severity Index.手部湿疹严重程度指数的反应性与可解释性。
Br J Dermatol. 2020 Apr;182(4):932-939. doi: 10.1111/bjd.18295. Epub 2019 Sep 5.